Afatinib named patient use program in advanced NSCLC with progression on prior therapy: experience from Asian center
Gee-Chen Chang, David Chi-Leung Lam, Chun-Ming Tsai, Yuh-Min Chen, Jin-Yuan Shih, Shyam Aggarwal, Shuhang Wang, Sang-We Kim, Young-Chul Kim, Ibrahim Wahid, Rubi Li, Wan-Teck Lim,
Virote Sriuranpong, Tsz Tong Chan, James Chih-Hsin Yang, Chong-Jen Yu, Wei-Yu Liao, Chao-Chi Ho, Robert M. Lorence, Philippe Carriere, Christina Raabe, Agnieszka Cseh, Keunchil Park
Learn more about the science behind this poster in the videos, papers and other materials below.
FOR HEALTHCARE PROFESSIONALS ONLY.
In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue